Our mission
Advancing toward a post-resistance era.
By delivering safe, structurally disruptive antimicrobials to patients globally.
01
Structurally disruptive
A structurally disruptive approach that resistant pathogens cannot route around.
02
Multi-modal
One patented composition acting across antibacterial, antiviral, and angiogenic fronts.
03
Global reach
Safe antimicrobials intended to reach patients at scale.
The target
The resistance crisis.
Multi-drug-resistant pathogens outpace conventional antibiotics because every single-site drug eventually selects for resistance. We target the WHO list of multi-drug-resistant pathogens with a mechanism that does not give resistance a foothold.
- — No observed resistance in 20+ yrs
- — WHO priority pathogens
- — Two patented assets
- — Three FDA pathways
The approach
One engine, three fronts.
A patented LBX242 composition, expressed across antibacterial, antiviral, and angiogenic fronts. Not a pipeline of unrelated molecules: one structurally disruptive engine, deployed three ways.
01
Antibacterial
Structural disruption that pathogens cannot route around.
02
Antiviral
Active against enveloped respiratory viruses at the point of entry.
03
Angiogenic
Promotes angiogenesis and supports tissue repair.
04
De-risked
Two patented assets across three expedited FDA pathways.
Regeneration
Not only defense. Repair.
Independent, peer-reviewed research documents the biological activity of the composition. The botanical matrix carries a continuous history of human use since 1996.
The same constituent is angiogenic: it promotes angiogenesis and supports tissue repair, addressing the conditions required for healing rather than symptom relief alone.
Continue